GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Cash From Other Investing Activities

Rakovina Therapeutics (TSXV:RKV) Cash From Other Investing Activities : C$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics Cash From Other Investing Activities?

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Rakovina Therapeutics's cash from other investing activities for the three months ended in Dec. 2024 was C$0.00 Mil. It means Rakovina Therapeutics received C$0.00 Mil from other investing activities. Rakovina Therapeutics's cash from other investing activities for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00 Mil.

Rakovina Therapeutics Cash From Other Investing Activities Historical Data

The historical data trend for Rakovina Therapeutics's Cash From Other Investing Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Cash From Other Investing Activities Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Cash From Other Investing Activities
- - - -

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash From Other Investing Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rakovina Therapeutics Cash From Other Investing Activities Calculation

Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cash From Other Investing Activities for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rakovina Therapeutics Cash From Other Investing Activities Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Cash From Other Investing Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Rakovina Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Cash From Other Investing Activities
Comparable Companies
TSXV:KNE XCNQ:GLOW TSXV:IBO TSX:APS TSXV:QPT TSXV:CYTO XCNQ:ASEP XCNQ:BIOV TSXV:XRTX XCNQ:LOBE VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
RKVTF:USA
Address
105 1008 Beach Avenue, Vancouver, BC, CAN, V6E 1T7
Website
https://www.rakovinatherapeutics.com
Rakovina Therapeutics Inc is a biopharmaceutical research company focused on the development of cancer treatments. Its work is based on technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using proprietary, generative AI platforms. By using AI, it can review and optimize drug candidates at a much greater pace than ever before. The company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
Executives
Jeffrey Bacha Senior Officer
Alfredo De Lucrezia Director, Senior Officer
Michael Liggett Director
Mads Daugaard Senior Officer
David Hyman Senior Officer
John Michael Langlands Senior Officer

Rakovina Therapeutics Headlines

No Headlines